Sera Prognostics, Inc.
3.4900-0.26 (-6.93%)
Oct 29, 4:00:00 PM EDT · NasdaqGM · SERA · USD
Key Stats
Market Cap
132.84MP/E (TTM)
-Basic EPS (TTM)
-0.85Dividend Yield
0%Recent Filings
8-K
PreTRM trial boosts outcomes
Sera Prognostics released an investor presentation on September 5, 2025, highlighting its PreTRM test's role in predicting preterm birth risks. Backed by the PRIME trial, it showed a 20% drop in neonatal morbidity, 22% fewer NICU admissions, and screening just four moms prevents one NICU day. With $108.5M in cash through 2028, Sera ramps up commercialization via Medicaid pilots and payer outreach. Forward-looking claims carry risks from clinical uncertainties.
10-Q
Q2 FY2025 results
Sera Prognostics posted Q2 revenue of $17K, down from $24K a year earlier but up from $38K in Q1, as the company ramps up commercialization of its PreTRM test following positive PRIME study results showing 25% reduced neonatal morbidity. Operating expenses held steady at $9.3M year-over-year, with R&D dropping 24% to $3.3M on PRIME wind-down, yet selling and marketing rose 66% to $1.8M amid team expansion. Net loss narrowed to $8.0M from $8.3M, or $0.16 per share on 49.1M diluted shares—better than $0.25 last year, with no anti-dilution flagged. Cash swelled to $108.5M after a $53.6M February offering, funding operations through 2028; free cash flow not disclosed in the 10-Q. No M&A or debt noted. Payer reimbursement hurdles persist as a key risk.
8-K
Q2 revenue dips; cash strong
Sera Prognostics reported Q2 2025 revenue of $17,000, down from $24,000 a year ago, with net loss narrowing to $8.0 million from $8.3 million amid flat operating expenses of $9.3 million. The company advanced Medicaid engagements in high-prematurity states and bolstered its team with key hires in commercial, market access, and investor relations roles. Cash reserves hit $108.5 million, funding operations through 2028. PRIME study results loom large this year.
8-K
Annual meeting elects directors
Sera Prognostics held its 2025 Annual Meeting on June 5, electing Jane F. Barlow, M.D., and Mansoor Raza Mirza, M.D., as Class I directors for three-year terms ending in 2028, with 14.4 million and 14.4 million votes in favor, respectively, amid 4.9 million withheld. Stockholders also ratified Ernst & Young LLP as auditors for the fiscal year ending December 31, 2025, with near-unanimous 24.3 million votes for. This routine governance refresh signals steady board continuity. No controversies surfaced.
8-K
Sera names CCO for growth push
Sera Prognostics appointed Lee Anderson as Chief Commercial Officer on May 8, 2025, to lead commercial expansion following the PRIME study's strong results. With over 30 years in healthcare sales and diagnostics, including key roles at Genomic Health and Exact Sciences where he drove nine years of revenue growth, Anderson will boost adoption of the PreTRM Test. This hire sharpens Sera's focus on market penetration. Yet risks like market acceptance loom large.
AWHL
Aspira Women's Health Inc.
0.49+0.01
BMRA
Biomerica, Inc.
2.79-0.14
CODX
Co-Diagnostics, Inc.
0.49-0.08
NTRA
Natera, Inc.
192.81+3.24
PFSA
Profusa, Inc.
0.29-0.00
SENS
Senseonics Holdings, Inc.
7.25+0.05
SHC
Sotera Health Company
16.58+0.02
SMLR
Semler Scientific, Inc.
25.99-1.23
SRDX
Surmodics, Inc.
26.93-0.43
UTMD
Utah Medical Products, Inc.
57.02-1.51